[1]徐艺威 周彤.选择性BET蛋白抑制剂在心血管疾病中的研究进展临床潜力[J].心血管病学进展,2025,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2025.012]
　XU Yiwei,ZHOU Tong.Research Progress and Clinical Potential of Selective BET Protein Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2025,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2025.012]
点击复制

选择性BET蛋白抑制剂在心血管疾病中的研究进展临床潜力()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年11期
页码:
1015
栏目:
综述
出版日期:
2025-11-25

文章信息/Info

Title:
Research Progress and Clinical Potential of Selective BET Protein Inhibitors in Cardiovascular Diseases
作者:
徐艺威 周彤
(内蒙古医科大学第三临床医学院 内蒙古包钢医院急诊医学科,内蒙古 包头 01400)
Author(s):
XU Yiwei; ZHOU Tong
(Department of EmergencyThe Third Clinical Medical College of Inner Mongolia Medical University,Inner Mongolia Baogang Hospital,Baotou 014010,Inner Mongolia,China)
关键词:
心血管疾病; 溴结构域和超末端结构域蛋白抑制剂; Apabetalone; 炎症; 脂质代谢
Keywords:
Cardiovascular disease;  Bromodomain and extra-terminal domain inhibitor;  Apabetalone;  Inflammation;  Lipid metabolism
DOI:
10.16806/j.cnki.issn.1004-3934.2025.012
摘要:
心血管疾病目前仍是全球死亡率最的疾病之一，其治疗依旧面临巨大挑战。BET蛋白抑制剂是一种通过调控基因表达来治疗疾病的新兴医疗手段，已在癌症、神经系统疾病和自身免疫性疾病等领域有着广泛应用，其中apabetalone作为首个口服选择性BET蛋白抑制剂，在心血管疾病患者中表现出极大的临床治疗潜力。
Abstract:
Cardiovascular diseases remain one of the leading causes of mortality worldwide,and their treatment continues to face significant challenges. Bromodomain and extra-terminal domain(BET)inhibitors are an emerging therapeutic approach that regulate gene expression and have been widely applied in the fields of cancer,neurological diseases,and autoimmune diseases. Among them,apabetalone,as the first orally selective BET protein inhibitor,has shown great clinical therapeutic potential in patients with cardiovascular diseases.This article systematically reviews the relevant progress of BET protein inhibitor in the field of cardiovascular diseases

参考文献/References:

[1] Sebastian SA,Padda I,Johal G. Cardiovascular-kidney-metabolic (CKM) syndrome:a state-of-the-art review[J]. Curr Probl Cardiol,2024,49(2):102344.

[2] Hummelgaard S,Vilstrup JP,Gustafsen C,et al. Targeting PCSK9 to tackle cardiovascular disease[J]. Pharmacol Ther,2023,249:108480.
[3] Neele AE,Willemsen L,Chen HJ,et al. Targeting epigenetics as atherosclerosis treatment:an updated view[J]. Curr Opin Lipidol,2020,31(6):324-330.
[4] Iudin MS,Khodarovich YM,Varizhuk AM,et al. A minireview on BET inhibitors:beyond bromodomain targeting[J]. Biomedicines,2025,13(3):594.
[5] Guo J,Zheng Q,Peng Y. BET proteins:biological functions and therapeutic interventions[J]. Pharmacol Ther,2023,243:108354.
[6] Napoli C,Coscioni E,de Nigris F,et al. Emergent expansion of clinical epigenetics in patients with cardiovascular diseases[J]. Curr Opin Cardiol,2021,36(3):295-300.
[7] Brandts J,Ray KK. Apabetalone -?ET protein inhibition in cardiovascular disease and Type 2 diabetes[J]. Future Cardiol,2020,16(5):385-395.
[8] Singh V,Kaur R,Kumari P,et al. ICAM-1 and VCAM-1:gatekeepers in various inflammatory and cardiovascular disorders[J]. Clin Chim Acta,2023,548:117487.
[9] Wang Y,Li M,Chen J,et al. Macrophage CAPN4 regulates CVB3-induced cardiac inflammation and injury by promoting NLRP3 inflammasome activation and phenotypic transformation to the inflammatory subtype[J]. Free Radic Biol Med,2023,208:430-444.
[10] Bian T,Li H,Liu H,et al. Apabetalone alleviates ligature-induced periodontitis by inhibiting M1 macrophage polarization via an immunometabolic shift[J]. Int Immunopharmacol,2025,150:114279.
[11] Nordén ES,Bendiksen BA,Bergo KK,et al. Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats[J]. ESC Heart Fail,2025,12(2):1304-1315.
[12] Penna C,Pagliaro P. Endothelial dysfunction:redox imbalance,NLRP3 inflammasome,and inflammatory responses in cardiovascular diseases[J]. Antioxidants (Basel),2025,14(3):256.
[13] Wang M,Huang Z,Li X,et al. Apabetalone,a BET protein inhibitor,inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis[J]. Pharmacol Res,2024,207:107306.
[14] van Linthout S. Shared mechanisms in cancer and cardiovascular disease:S100A8/9 and the NLRP3 inflammasome:JACC:cardiooncology state-of-the-art review[J]. JACC CardioOncol,2024 Dec 6:S2666-0873(24)00370-3.
[15] Karantas ID,Okur ME,Okur N,et al. Dyslipidemia management in 2020:an update on diagnosis and therapeutic perspectives[J]. Endocr Metab Immune Disord Drug Targets,2021,21(5):815-834.
[16] Ganda OP. Triglyceride-rich lipoproteins,remnant-cholesterol,and atherosclerotic cardiovascular disease[J]. Curr Opin Lipidol,2023,34(3):105-113.
[17] Wang M,Huang Z,Zhu Y,et al. The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota[J]. Kidney Int Rep,2025,10(2):522-34.
[18] Tsujikawa LM,Fu L,Das S,et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism[J]. Clin Epigenetics,2019,11(1):102.
[19] Wasiak S,Tsujikawa L M,Daze E,et al. Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells[J]. Atherosclerosis,2023,364:10-19.
[20] Banach M,Surma S,Reiner Z,et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)[J]. Cardiovasc Diabetol,2022,21(1):263.
[21] Wasiak S,Fu L,Daze E,et al. The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation[J]. Transl Neurosci,2023,14(1):20220332.
[22] Li T,Zhang W,Wang Y,et al. Lysine-targeting,covalent inhibitors of bromodomain BD1 of BET proteins in live cells and animals[J]. Angew Chem Int Ed Engl,2025:e202424832.
[23] Marbach D,Brouer-Visser J,Brennan L,et al. Immune modulation in solid tumors:a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)[J]. BMC Cancer,2025,25(1):500.
[24] Rampal RK,Grosicki S,Chraniuk D,et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis:a randomized phase 3 trial[J]. Nat Med,2025,31(5):1531-1538.
[25] Zhang Y,Desai N,Connolly D. The use of apabetalone in reducing cardiovascular outcomes,based on the current evidence and trials[J]. Eur Cardiol,2025,20:e04.
[26] Cescon DW,Hilton J,Morales Murilo S,et al. A Phase Ⅰ/Ⅱ study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer[J]. Clin Cancer Res,2024,30(2):334-343.
[27] Amrutkar RD,Amesar MV,Chavan LB,et al. Precision targeting of BET proteins—Navigating disease pathways,inhibitor insights,and shaping therapeutic frontiers:a comprehensive review[J]. Curr Drug Targets,2025,26(3):147-166.
[28] Laddha AP,Seyednejad A,Donepudi AC,et al. Inhibition of bromodomain and extra-terminal (BET) proteins with JQ1 exacerbates acetaminophen-induced hepatotoxicity by altering detoxification pathways and oxidative stress responses[J]. Chem Biol Interact,2025,413:111491.
[29] Wang ZQ,Zhang ZC,Wu YY,et al. Bromodomain and extraterminal (BET) proteins:biological functions,diseases,and targeted therapy[J]. Signal Transduct Target Ther,2023,8(1):420.
[30] Brown JA,Bal J,Simeoni M,et al. A randomized study of the safety and pharmacokinetics of GSK3358699,a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor[J]. Br J Clin Pharmacol,2022,88(5):2140-2155.
[31] Ma L,Wang J,Zhang Y,et al. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes[J]. Cancer Biol Ther,2022,23(1):1-15.
[32] Wang L,Huan XJ,Song SS,et al. UBE4B modulates BET inhibitor sensitivity via KLHL22-JAK2-PIM1 axis in hepatocellular carcinoma[J]. Biochem Pharmacol,2025,237:116943.
[33] Maierean S,Webb R,Banach M,et al. The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events[J]. Eur Heart J Open,2022,2(4):oeac039.
[34] Shishikura D,Kataoka Y,Honda S,et al. The effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque:insights from the ASSURE trial[J]. Am J Cardiovasc Drugs,2019,19(1):49-57.
[35] Wasiak S,Gilham D,Daze E,et al. Epigenetic modulation by apabetalone counters cytokine-driven acute phase response in vitro,in mice and in patients with cardiovascular disease[J]. Cardiovasc Ther,2020,2020:9397109.
[36] Toth PP,Schwartz GG,Nicholls S J,et al. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome,type 2 diabetes,and moderate to high likelihood of non-alcoholic fatty liver disease[J]. Am J Prev Cardiol,2022,11:100372.
[37] Dhulkifle H,Diab MI,Algonaiah M,et al. Apabetalone (RVX-208):a potential epigenetic therapy for the treatment of cardiovascular,renal,neurological,viral,and cancer disorders[J]. ACS Pharmacol Transl Sci,2024,7(3):546-559.
[38] Kalantar-Zadeh K,Schwartz GG,Nicholls SJ,et al. Effect of apabetalone on cardiovascular events in diabetes,CKD,and recent acute coronary syndrome:results from the BETonMACE randomized controlled trial[J]. Clin J Am Soc Nephrol,2021,16(5):705-716.
[39] Ray KK,Nicholls SJ,Buhr KA,et al. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes:a randomized clinical trial[J]. Jama,2020,323(16):1565-1573.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
　REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(11):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
　YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
　ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
　QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
　JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(11):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(11):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2026-03-06